Replies to post #38592 on Biotech Values

[dewophile]

re onxx drop..I don't follow the company so not sure. Melanoma is a much larger market than renal cell CA, and apparently much of the valuation was placed on future expansion versus the currently approved indication. My only point is that the biotech world is littered with the carcasses of companies with once-huge valuations that have plummetted based on failure to deliver in this indication (also see DD's post re CA vaccines). I would view melanoma trials in general as particularly high risk given the precedent (although the upside is huge given the size of the market)